Thomas Briot

Associate Professor & Hospital Pharmacist

Université Claude Bernard Lyon 1

France

Research Interests

Explore related searches

Professors in France Professors in Microbiology Microbiology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Thomas Briot is an Associate Professor and Hospital Pharmacist at Université Claude Bernard Lyon 1, France. His research areas include phage therapy, fecal microbiota transplantation, and pharmaceutical innovations, as reflected in his recent articles. He has contributed to the understanding of phage therapy implementation, clinical outcomes in microbiota transplantation, and novel drug delivery approaches in pharmacology.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Collaborators (5)

Frederic Lagarce

Prof. Biopharmaceutics - Director of Pharmacy department

Université de Lorraine Faculté de Pharmacie

FRANCE

View details

Philip Chennell

Université Clermont Auvergne

FRANCE

View details

Jérôme Josse

Université Claude Bernard Lyon 1

FRANCE

View details

Frédéric Marçon

Assistant lecturer

Université de Picardie Jules Verne

FRANCE

View details

Nicolas BENECH

Assistant Professor

Hospices Civils de Lyon

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas Briot

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Ultraviolet C Decontamination Devices in a Hospital Pharmacy: An Evaluation of Their Contribution

Development of a 50% (w/v) aluminium chloride hexahydrate solution as haemostatic agent

Recommendations on training objectives and staff qualification for the manual preparation of capsules in pharmacy

Real-time monitoring by interferometric light microscopy of phage suspensions for personalised phage therapy

Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic programme

Impact of Clinical and Pharmacological Parameters on Faecal Microbiota Transplantation Outcome in Clostridioides difficile Infections: Results of a 5‐Year French National Survey

Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Can Be the Best Therapeutic Option in Severely Immunocompromised Patients Depending on a Case-by-Case Assessment of the Benefit-to-Risk Ratio

Les virus au service de la santé : les bactériophages

Paving the way for phage therapy using novel drug delivery approaches

Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection

Collaborators (5)

Frederic Lagarce

Philip Chennell

Jérôme Josse

Frédéric Marçon

Nicolas BENECH

Make your next move.